EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Disproportionality Analysis of Tirzepatide vs. Semaglutide and Liraglutide: System Organ Class-Level Post-Marketing Reporting Patterns in EudraVigilance

Ruxandra Cristina Marin iD, Cosmin Mihai Vesa iD, Delia Mirela Tit iD, Andrei-Flavius Radu iD, Gabriela S Bungau

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27072988 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Ruxandra Cristina Marin und 4 weiteren Autor:innen. Beteiligte Einrichtung: Doctoral School of Biological and Biomedical Sciences, University of Oradea, 410087 Oradea, Romania. Hauptthemen laut MEDLINE: Glucagon-Like Peptides, Liraglutide, Hypoglycemic Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Oradea, University of Oradea, Oradea, Romania https://ror.org/00wzhv093.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) receptor agonist, introduces a mechanistically distinct approach within incretin-based therapies. While its efficacy is established, real-world data comparing post-marketing safety with established GLP-1 receptor agonists remain limited. This study assessed System Organ Class (SOC)-level reporting patterns for tirzepatide versus semaglutide and liraglutide using EudraVigilance data. Aggregated individual case safety reports (ICSRs) were analyzed using pairwise disproportionality analyses based on a case/non-case approach. Reporting odds ratios (RORs) with 95% confidence intervals were calculated. False discovery rate (FDR) correction using the Benjamini–Hochberg procedure and sensitivity analyses restricted to serious and healthcare professional–reported cases were performed to assess robustness. After FDR adjustment, 20 SOCs were significant in tirzepatide–semaglutide and 23 in tirzepatide–liraglutide comparisons; eight SOCs remained significant across all analytical conditions. Compared with semaglutide, tirzepatide showed higher reporting for immune (ROR 1.97, 95% CI 1.75–2.21) and hepatobiliary disorders (ROR 1.71, 95% CI 1.61–1.82). Versus liraglutide, higher odds occurred for musculoskeletal (ROR 2.02, 95% CI 1.85–2.21) and psychiatric disorders (ROR 2.14, 95% CI 1.99–2.30), and lower odds for neoplasms (ROR 0.28, 95% CI 0.26–0.31). Tirzepatide shows heterogeneous reporting patterns compared with GLP-1 receptor agonists, with consistent excess reporting for hepatobiliary, immune, and musculoskeletal disorders. These findings are hypothesis-generating and warrant confirmation in exposure-adjusted studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like PeptidesLiraglutideHypoglycemic AgentsTirzepatideSemaglutideHumansGlucagon-Like Peptide-1 Receptor AgonistsPharmacovigilanceAdverse Drug Reaction Reporting Systems

Stichwörter der Autor:innen

EudraVigilancedual GIP/GLP-1 receptor agonistincretin signalingliraglutidepharmacovigilancepost-marketing safetyreporting odds ratiosemaglutidetirzepatide

Substanzen

TirzepatideSemaglutideGlucagon-Like PeptidesLiraglutideHypoglycemic AgentsGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Doctoral School of Biological and Biomedical Sciences, University of Oradea, 410087 Oradea, Romania.
  • Department of Pharmacology, Clinical Pharmacology and Pharmacotherapy, Faculty of Medicine, "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania.
  • Department of Preclinical Disciplines, Faculty of Medicine and Pharmacy, University of Oradea, 410073 Oradea, Romania.
  • Department of Pharmacy, Faculty of Medicine and Pharmacy, University of Oradea, 410028 Oradea, Romania.
  • Department of Psycho-Neuroscience and Recovery, Faculty of Medicine and Pharmacy, University of Oradea, 410073 Oradea, Romania.

ORCID-Profile: Ruxandra Cristina Marin, Cosmin Mihai Vesa, Delia Mirela Tit, Andrei-Flavius Radu

Förderung

  • University of Oradea
  • University of Oradea, Oradea, Romania https://ror.org/00wzhv093

Zitieren

APA

Marin, R. C., Vesa, C. M., Tit, D. M., Radu, A. F., & Bungau, G. S. (2026). Disproportionality Analysis of Tirzepatide vs. Semaglutide and Liraglutide: System Organ Class-Level Post-Marketing Reporting Patterns in EudraVigilance. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27072988

Vancouver

Marin RC, Vesa CM, Tit DM, Radu AF, Bungau GS. Disproportionality Analysis of Tirzepatide vs. Semaglutide and Liraglutide: System Organ Class-Level Post-Marketing Reporting Patterns in EudraVigilance. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27072988

BibTeX
@article{Marin2026,
  author = {Marin, Ruxandra Cristina and Vesa, Cosmin Mihai and Tit, Delia Mirela and Radu, Andrei-Flavius and Bungau, Gabriela S},
  title = {Disproportionality Analysis of Tirzepatide vs. Semaglutide and Liraglutide: System Organ Class-Level Post-Marketing Reporting Patterns in EudraVigilance},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27072988}
}
Kostenlos starten →